Testing ES502 for Advanced Pancreatic and Other Cancers
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-stage trial tests a new drug called ES502 for patients with advanced cancers (including pancreatic cancer) that have a specific genetic mutation and certain immune markers. The study aims to find the right dose and see if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced cancer (pancreatic, colorectal, lung, or other types) that hasn't responded to standard treatment or for which no standard treatment exists
- Your tumor has a RAS G12V mutation and specific HLA immune markers
- You have a tumor sample available from the past 5 years for genetic testing
- Your overall health is good enough for treatment (ECOG score 0–1, expected to live longer than 3 months)
- Your blood counts, liver, kidney, and heart function are adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
This trial tests a new drug combined with other treatments for advanced pancreatic cancer. It aims to see if the combination can help people whose cancer has a specific genetic change called RAS mutation.
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
This trial tests an experimental drug for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.